BI 655075

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyHemorrhage

Phase 1

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

CompletedNCT01688830

Boehringer IngelheimHealthy

Start: 2012-09-30End: 2013-11-30Updated: 2016-06-23

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

CompletedNCT01955720

Boehringer IngelheimHemorrhage

Start: 2013-09-30End: 2014-08-31Updated: 2016-02-11

Related Papers

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

Research and Practice in Thrombosis and Haemostasis2017-08-0517 citations

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

2017-01-0146 citations

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

2015-06-15222 citations